With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

Sensorion has two therapeutic solutions being evaluated in clinical trials:
SENS-111 and SENS-401

2018 08 Pipeline

Latest news

  • 07 Dec 2018

    Sensorion announces a publication in Hearing Research on kinetics of prestin blood levels after noise trauma-induced hearing loss. Read

  • 27 Nov 2018

    Sensorion announces completion of patient enrollment and dosing in Seliforant phase 2a study. Read

Patient center

Corporate presentation